Georgia Bio Sign-on to State Medical Technology Alliance HHS & CMS Letter

Georiga Bio sign-on to the State Medical Technology Alliance (SMTA) letter to U.S. Department of Health and Human Services (HHS) and Centers for Medicare & Medicaid. Please see the language below.


The Honorable Alex M. Azar II
Secretary
U.S. Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201

The Honorable Seema Verma
Administrator
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244


Dear Secretary Azar and Administrator Verma:

As members of the State Medical Technology Alliance (SMTA), we are state and regional life sciences associations representing biotechnology, medical device companies, universities, research institutions, and venture capital firms across the country, all dedicated to developing and delivering life-enhancing and life-saving products, we write to express our strong support for your leadership in the U.S. Department of Health and Human Services’ (HHS) efforts to provide coverage for transformative medical devices that are approved as breakthrough devices by the FDA.

The COVID-19 pandemic highlighted the need for our nation’s health care system to better align care for patients.  We commend HHS for taking swift action to create appropriate waivers and incentives across different health care stakeholders to better address this devastating disease.  Providing patients with access to breakthrough devices would further this push to align care for patients by promoting innovation and providing patients with the latest in life-changing medical technology.

The medical technology industry is an important and thriving sector in the U.S. economy, creating jobs in all 50 states and representing a sizable portion of the nation’s Gross Domestic Product.  The industry is responsible for about 1.9 million jobs in the U.S. and an economic output of approximately $381 billion annually.

Access to state-of-the art medical technology and diagnostics can help to improve care and patient outcomes, and CMS has acknowledged the value of breakthrough products by including a Breakthrough Product Pathway for new technology add-on payments (NTAP) in the Final Rule on the FY 2020 Inpatient Prospective Payment System. 

We commend HHS and CMS for these efforts and urge you to take the next step by providing coverage for all medical devices that are approved and cleared as FDA-designated breakthrough in all settings.  Providing this needed certainty will help ensure the next round of truly life-changing innovation can get to the patients who need them as quickly as possible.

As members of the SMTA, we look forward to working with the Administration to finalize this critical effort.



Sincerely,


Arizona BioIndustry Association (AZBio)

Biocom: Life Science Association of California

BioFlorida

BioForward Wisconsin

BioOhio

Bioscience Association of West Virginia (BioWV)

BioUtah

California Life Sciences Association (CLSA)

Colorado BioScience Association (CBSA)

Florida Medical Manufacturers Consortium (FMMC)

Georgia Bio

Healthcare Institute of New Jersey (HINJ)   

Illinois Biotechnology Innovation Organization (iBIO)

Indiana Health Industry Forum (IHIF)

Indiana Medical Device Manufacturers Council (IMDMC)

Iowa Biotechnology Association (IowaBio)

Kentucky Life Sciences Council

Life Sciences Pennsylvania

Life Science Tennessee

Life Science Washington

Massachusetts Medical Device Industry Council (MassMEDIC)

Medical Alley Association

MedTech Association New York

Michigan Biosciences Industry Association (MichBio)

Mississippi Biotechnology Association

Missouri Biotechnology Association (MOBIO)

NCBIO

SCBIO

Southeast Life Sciences

Texas Healthcare & Bioscience Institute (THBI)

October 20, 2026
J.P. Morgan Healthcare Week is one of the most business-forward weeks of the year for the life sciences industry—a time when companies, investors, strategic partners, and industry leaders come together to build relationships, explore investment opportunities, and advance innovation. GLS is helping our community make the most of the week with opportunities to connect, partner, and engage with the broader life sciences investment community. Here are a few events and member benefits to add to your calendar. State Bio Friends Kickoff 2027 📅 January 10 | 4:00–7:00 PM 📍 The Marker San Francisco 🎟️ To request a registration code, contact Stacey Bowlin at sbowlin@galifesciences.org . RESI JPM 2027 GLS is proud to partner with Life Science Nation to offer our community $300 off registration for RESI JPM 2027 . RESI JPM connects early-stage life sciences companies with investors, strategic partners, and industry leaders through networking, partnering, and programming focused on advancing innovation and investment. 📍 In person: January 11–12 | San Francisco Marriott Marquis 📅 Virtual partnering: January 13, 18, and 19 🎟️ Please use code GABIO to r eceive $300 off registration Biotech Showcase GLS is pleased to partner with Biotech Showcase to help connect our community with this important industry gathering. Taking place January 11-13, Biotech Showcase is a premier investor conference for private and emerging publicly traded biotech companies, bringing together innovators and investors to explore partnerships and financing opportunities. 📅 January 11–13 📍Hilton San Francisco Union Square 🎟️ Please use cod e supGALS2027 to receive $200 off registration Fierce JPM Week 📅 January 12–13 📍 Hyatt Regency San Francisco 🎟️ Secure your pass We encourage our members and partners to take advantage of these opportunities and represent Georgia’s growing life sciences community on the national stage. We look forward to connecting with you in San Francisco!
October 15, 2026
As pharmaceutical and biotechnology companies expand U.S. manufacturing operations, a growing demand for specialized talent underscores the importance of industry-driven workforce development. October 16, 2026 | Georgia Life Sciences The United States is experiencing a resurgence in domestic manufacturing investment, with pharmaceutical and biotechnology companies announcing major expansions and new production facilities. But as investment accelerates, a critical challenge is emerging: ensuring that a skilled workforce is available to support this growth. According to a Deloitte and The Manufacturing Institute study , approximately 3.8 million manufacturing positions could need to be filled nationwide through 2033 , with as many as 1.9 million potentially remaining unfilled due to workforce and skills gaps. While these projections span the broader manufacturing sector, the implications for life sciences are significant. Biomanufacturing's Growing Talent Challenge A recent PharmaVoice article examines how pharmaceutical companies are responding to growing competition for skilled workers, particularly in specialized roles such as automation engineering, quality assurance, regulatory affairs, process engineering, and manufacturing operations. These positions are essential to bringing new facilities online, maintaining regulatory compliance, and ensuring safe, reliable production. The challenge extends beyond competition among pharmaceutical manufacturers. Life sciences companies are increasingly competing with industries such as semiconductors, aerospace, energy, and advanced manufacturing for workers with similar technical skills. Some companies are responding by investing directly in regional education and training partnerships. Eli Lilly, for example, recently committed $15 million to San Jacinto College in Texas, including $12.5 million dedicated to workforce training, alongside a major manufacturing expansion in the Houston area. The message is increasingly clear: Workforce planning must begin alongside facility planning, not after construction is complete. What This Means for Georgia Georgia has an opportunity to build on its growing biomanufacturing presence, established industry base, research universities, and technical education infrastructure. However, continued success will depend on ensuring that workforce development keeps pace with industry investment. As manufacturing technologies evolve, employers will need workers with expertise in automation, digital systems, quality control, and advanced production processes. Traditional education pathways alone may not be sufficient to meet these changing needs. That makes stronger collaboration among employers, educational institutions, workforce organizations, and policymakers increasingly important. Through its Manufacturing Council, Georgia Life Sciences is working to strengthen industry engagement and better understand employers' evolving workforce needs. These conversations help identify opportunities to align education and training with the skills companies need today and anticipate those they will require tomorrow. The Georgia Life Sciences Institute also supports the long-term talent pipeline through education and workforce initiatives designed to introduce students and educators to life sciences careers and strengthen connections between education and industry. Looking Ahead: Talent as a Competitive Advantage As states compete to attract life sciences investment, workforce readiness will increasingly influence where companies choose to expand and how successfully those investments translate into long-term economic growth. For Georgia, the opportunity is not simply to attract new facilities but to build the talent ecosystem necessary to sustain them. That requires earlier employer engagement, flexible training models, stronger industry-education partnerships, and continued attention to emerging technologies that are changing the nature of manufacturing work. The next chapter of biomanufacturing growth will be defined not only by where companies invest, but by where they can find, develop, and retain the talent needed to succeed. Related Reading Deloitte: Taking Charge — Manufacturers Support Growth With Active Workforce Strategies PharmaVoice: Pharma's Manufacturing Boom Has a Workforce Problem
October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →
MORE POSTS